| Good morning Wake-Up Watchlisters! Tell your barista to make it a double-shot as we work our way through hump-day. The markets are green across the board, albeit a very light shade of green. Heck these days we'll take what we can! We should see the minutes from the most recent Fed meeting later today and the December jobs report will be released in full at the end of the week, perhaps the GOP will have settled on a new speaker of the house by then. There is still a ton of confusion out there in the markets, and it can often be distracting even to the savviest of investors. Our members have been learning how to shut out the noise and follow what the smartest guys in the room are doing. We've been tracking the company insiders and making huge gains, regardless of the market. Check out how we're pulling it off. Here's a look at the top-moving stocks this morning. Vera Therapuetics (Nasdaq: VERA) Vera Therapeutics (VERA) is down 61.75% premarket. The biotech company last night released top-line data from the phase 2 trial of a drug to help patients with kidney disease. While the results of the trials are good enough to move into the 3rd phase, they were not good enough for investors. The drug produced reductions in urine proteins, a key metric, by 33%, not enough to meet the 40-50% reduction that the company and medical field have been striving for. While the path to success has been tough for biotech stocks, there are still innovative companies that stand a chance for massive gains in the future. Even better – you can trade some of these companies at cheap prices. Right now, our friend Alexander Green is pounding the table on a medical device company he's calling 'the biggest investment opportunity in 37 years.' ATLIS Motor Vehicles (AMV) ATLIS Motor Vehicles is up 42.76% premarket. The start-up mobility technology company has been working towards the production of its own AMV battery cells up to the 500-mile range with the goal of being the first in the industry to charge in less than 15 minutes. Headquartered in Mesa, Arizona, ATLIS is 2 months into mass trials for its new class of batteries, the last phase in the process before full commercial manufacturing begins. ATLIS is just one of the several EV companies poised to make a greater push in 2023. There is another startup you should know about that still sits below $25 a share. This company "has better claim the most to be the next Tesla" according to the Wall Street Journal. Our friend Andy Snyder took a deep dive into their tech and found some pretty incredible things. See why Andy thinks this could be the next big EV company. | 
Post a Comment
Post a Comment